All > Macular Edema > California

Suprachoroidal Triamcinolone acetonide 2.4mg for Diabetic Macular Edema

Phase-Based Progress Estimates
1
Effectiveness
2
Safety
Diabetic Macular EdemaTriamcinolone Acetonide - Drug
Eligibility
18+
All Sexes
What conditions do you have?
Select

Study Summary

The purpose of this clinical trial is to evaluate the safety and tolerability of suprachoroidal microcatheterization with the Oxulumis® device for a randomized treatment with two dose levels of Triesence® in subjects with Diabetic Macular Edema.

Eligible Conditions
  • Diabetic Macular Edema

Treatment Effectiveness

Effectiveness Progress

1 of 3

Similar Trials

1
Participating to Boost Meal Participation
1
FF-10850 Topotecan Liposome Injection
1
Syntocinon

Study Objectives

2 Primary · 0 Secondary · Reporting Duration: 24 Weeks

24 Weeks
Frequency of adverse device effects and frequency of serious adverse device effects
Frequency of ocular adverse events, systemic adverse events, serious, and treatment-emergent non-serious adverse events

Trial Safety

Safety Progress

2 of 3
This is further along than 68% of similar trials

Similar Trials

1
Participating to Boost Meal Participation
1
FF-10850 Topotecan Liposome Injection
2
Syntocinon

Trial Design

2 Treatment Groups

Suprachoroidal Triamcinolone acetonide 2.4mg
1 of 2
Suprachoroidal Triamcinolone acetonide 4.0 mg
1 of 2

Experimental Treatment

20 Total Participants · 2 Treatment Groups

Primary Treatment: Suprachoroidal Triamcinolone acetonide 2.4mg · No Placebo Group · Phase 2

Suprachoroidal Triamcinolone acetonide 2.4mgExperimental Group · 2 Interventions: Triamcinolone Acetonide, Semi-automated Suprachoroidal Microcatheter · Intervention Types: Drug, Device
Suprachoroidal Triamcinolone acetonide 4.0 mgExperimental Group · 2 Interventions: Triamcinolone Acetonide, Semi-automated Suprachoroidal Microcatheter · Intervention Types: Drug, Device
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
Triamcinolone Acetonide
2017
Completed Phase 4
~3470

Trial Logistics

Trial Timeline

Screening: ~3 weeks
Treatment: Varies
Reporting: 24 weeks

Who is running the clinical trial?

Oxular LimitedLead Sponsor
1 Previous Clinical Trials
Friedrich Asmus, MDStudy DirectorOxular Limited
1 Previous Clinical Trials

Eligibility Criteria

Age 18+ · All Participants · 4 Total Inclusion Criteria

Mark “Yes” if the following statements are true for you:
You have type 1 or type 2 diabetes mellitus.
You have diabetic macular edema involving the center of the fovea in the study eye.
References

Unbiased ResultsWe believe in providing patients with all the options.
Your Data Stays Your DataWe only share your information with the clinical trials you're trying to access.
Verified Trials OnlyAll of our trials are run by licensed doctors, researchers, and healthcare companies.
Back to top